Stevens Capital Management LP bought a new position in shares of Meridian Bioscience Inc. (NASDAQ:VIVO) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 16,999 shares of the company’s stock, valued at approximately $243,000.

Other large investors have also recently added to or reduced their stakes in the company. Prudential Financial Inc. increased its stake in Meridian Bioscience by 280.6% in the 2nd quarter. Prudential Financial Inc. now owns 273,330 shares of the company’s stock worth $4,305,000 after purchasing an additional 201,519 shares in the last quarter. Aperio Group LLC increased its stake in Meridian Bioscience by 40.0% in the 2nd quarter. Aperio Group LLC now owns 51,385 shares of the company’s stock worth $809,000 after purchasing an additional 14,682 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Meridian Bioscience by 29.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 39,672 shares of the company’s stock worth $625,000 after purchasing an additional 8,954 shares in the last quarter. Parametric Portfolio Associates LLC increased its stake in Meridian Bioscience by 19.2% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 191,114 shares of the company’s stock worth $3,010,000 after purchasing an additional 30,838 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Meridian Bioscience by 16.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,667,971 shares of the company’s stock worth $26,271,000 after purchasing an additional 240,143 shares in the last quarter. 87.68% of the stock is currently owned by hedge funds and other institutional investors.

In other Meridian Bioscience news, Chairman John A. Kraeutler bought 7,000 shares of the stock in a transaction on Thursday, August 24th. The shares were bought at an average price of $13.67 per share, with a total value of $95,690.00. Following the purchase, the chairman now directly owns 345,230 shares in the company, valued at approximately $4,719,294.10. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 2.30% of the company’s stock.

A number of equities analysts recently weighed in on the company. Zacks Investment Research cut Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Tuesday, October 24th. Canaccord Genuity reissued a “hold” rating and issued a $14.00 price target on shares of Meridian Bioscience in a research note on Friday, October 13th. Finally, BidaskClub cut Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Two equities research analysts have rated the stock with a sell rating and four have given a hold rating to the company. The company has an average rating of “Hold” and a consensus target price of $11.50.

Meridian Bioscience Inc. (NASDAQ VIVO) opened at $14.90 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 4.42 and a current ratio of 6.47. Meridian Bioscience Inc. has a 12 month low of $10.75 and a 12 month high of $18.58. The firm has a market capitalization of $626.72, a PE ratio of 21.84 and a beta of 0.89.

Meridian Bioscience (NASDAQ:VIVO) last released its earnings results on Thursday, November 9th. The company reported $0.15 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.15. Meridian Bioscience had a return on equity of 17.07% and a net margin of 10.74%. The company had revenue of $49.70 million for the quarter, compared to analysts’ expectations of $48.28 million. During the same quarter in the previous year, the business posted $0.14 EPS. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. equities research analysts forecast that Meridian Bioscience Inc. will post 0.66 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, November 30th. Shareholders of record on Monday, November 20th will be paid a dividend of $0.125 per share. The ex-dividend date is Friday, November 17th. This represents a $0.50 annualized dividend and a yield of 3.36%. Meridian Bioscience’s dividend payout ratio (DPR) is presently 98.04%.

ILLEGAL ACTIVITY WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/stevens-capital-management-lp-buys-new-holdings-in-meridian-bioscience-inc-vivo/1719372.html.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience Inc. (NASDAQ:VIVO).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.